Long non-coding RNAs (lncRNAs) have emerged as important regulators of cancer progression. Super enhancers (SE) play a role in tumorigenesis and regulate the expression of specific lncRNAs. We examined the role of , also named , in cutaneous squamous cell carcinoma (cSCC). Elevated () expression was detected in cSCC cells, and expression was downregulated by SE inhibitors THZ1 and JQ1 and via the MEK1/ERK1/2 pathway. Increased expression of () was noted in tumor cells in cSCCs and their metastases compared to normal skin, actinic keratoses, and cSCCs in situ. Higher () expression was noted in metastatic cSCCs than in non-metastatic cSCCs. RNA-seq analysis after () knockdown revealed significantly regulated GO terms , , , and KEGG pathway Among the top-regulated genes were , , and . Knockdown of () resulted in decreased production of MMP-1 and MMP-13 by cSCC cells, suppressed invasion of cSCC cells through collagen I, and growth of human cSCC xenografts in vivo. Based on these observations, () was named (super enhancer and ERK1/2-Regulated Long Intergenic non-protein coding transcript Overexpressed in Carcinomas). These results reveal the role of in cSCC invasion and identify it as a potential therapeutic target in advanced cSCC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406669 | PMC |
http://dx.doi.org/10.3390/cancers14163980 | DOI Listing |
Cancer Immunol Immunother
January 2025
Institute of Photomedicine, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China.
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer, originating from the malignant proliferation of squamous epithelial cells. However, its pathogenesis remains unclear. To further explore the mechanisms underlying cSCC, we analyzed the data from one single-cell RNA sequencing study and discovered a significant upregulation of tryptophan 2,3-dioxygenase (TDO2) in the cancer-associated fibroblasts (CAFs).
View Article and Find Full Text PDFJ Clin Invest
January 2025
Department of Dermatology, and.
J Transl Med
December 2024
Tongji Medical College, Maternal and Child Health Hospital of Hubei Province, Huazhong University of Science and Technology, Wuhan, Hubei Province, 430070, China.
Background: As a prevalent and deadly malignant tumor, the treatment outcomes for late-stage patients with cervical squamous cell carcinoma (CSCC) are often suboptimal. Previous studies have shown that tumor progression is closely related with tumor metabolism and microenvironment reshaping, with disruptions in energy metabolism playing a critical role in this process. To delve deeper into the understanding of CSCC development, our research focused on analyzing the tumor microenvironment and metabolic characteristics across different regions of tumor tissue.
View Article and Find Full Text PDFArch Dermatol Res
December 2024
Department of Burn and Plastic Surgery, Guizhou Provincial People's Hospital, Guiyang, Guizhou Province, 550002, China.
Cutaneous squamous cell carcinoma (CSCC) is a malignant skin tumor characterized by the abnormal proliferation of keratinocytes. Immune cells have a very important role in the development of CSCC. Hence, it was vital to screen the immune cell-related biomarkers for the treatment of CSCC.
View Article and Find Full Text PDFCancer Genomics Proteomics
December 2024
University Medical Center Göttingen, Department of Gynecology and Obstetrics, Göttingen, Germany
Background/aim: G protein-coupled estrogen receptor 1 (GPER1) appears to play a tumor-suppressive role in cervical squamous cell carcinoma (CSCC)GPER1 suppression leads to significantly increased expression of serpin family E member 1 (SERPINE1)/protein plasminogen activator inhibitor type 1 (PAI-1). The question arises, what role does SERPINE1/PAI-1 play in GPER1-dependent tumorigenic potential of CSCC.
Materials And Methods: SiHa and C33A CSCC cells were treated with GPER1 agonist G1 or antagonist G36.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!